Clinical Trials

108 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Cholangiocarcinoma

NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Phase NA Not yet recruiting

60 enrolled

Other solid neoplasm

Solid Tumors

NCT07417800 2026-02-18

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

1,000 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT07405164 2026-02-12

MK-6482-043

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07290894 2025-12-18

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT07277972 2025-12-11

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Phase 3 Not yet recruiting

36 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

450 enrolled

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

28 enrolled

Advanced Endometrial Cancer

NCT07263360 2025-12-04

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Phase 4 Not yet recruiting

29 enrolled

BTC

NCT07160361 2025-09-16

Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB

56 enrolled

Carcinoma, Hepatocellular

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

65 enrolled

Biliary Tract Neoplasms

NCT07131501 2025-08-20

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

48 enrolled

Phase 1/2 Not yet recruiting

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07096609 2025-07-31

LONGIST

48 enrolled

Sarcoma

GIST

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Phase NA Not yet recruiting

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT07014150 2025-06-10

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

30 enrolled

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Head & Neck

Thyroid Neoplasms

NCT06984718 2025-05-22

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

120 enrolled

Carcinoma, Hepatocellular

NCT06919848 2025-04-09

Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)

74 enrolled

Biliary Tract Neoplasms

NCT06884982 2025-03-19

An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib

30 enrolled